Laura Panjwani

Articles

Radiation/Immunotherapy Combos Slow to Gain Traction, But Have Potential in Prostate Cancer

January 20th 2016

Steven Finkelstein, MD, explains why radiation and immunotherapy may be an effective combination in prostate cancer.

Novel Approaches Explored in HER2-Positive Gastric Cancer

January 18th 2016

Yelena Y. Janjigian, MD, discusses possible causes of the negative LOGiC trial results, HER2 as a driver in esophagogastric cancer, and what the future holds for lapatinib.

Expert Discusses Emerging Agents and the Future of Follicular Lymphoma

January 18th 2016

John P. Leonard, MD, discusses the potential for lenalidomide, idelalisib, and ibrutinib in follicular lymphoma, possible combination therapies, and challenges that remain in the treatment of the disease.

Expert Discusses Emerging Treatments, Immunotherapy Potential in pNETs

January 14th 2016

Pamela L. Kunz, MD, discusses several recent studies that shown promise for the treatment of pancreatic neuroendocrine tumors (NETs), as well as other ongoing trials investigating the potential of immunotherapies in NETs.

Hope Rugo on Pembrolizumab's Potential in ER+/HER2- Breast Cancer

January 12th 2016

Hope Rugo, MD, discusses the phase Ib KEYNOTE-028 trial and the impact of its results thus far, as well as the design, findings, and next steps for the trial.

Atezolizumab/Vemurafenib Combo Shows Clinical Activity in BRAF+ Melanoma

January 12th 2016

The combination of atezolizumab (MPDL3280A) and vemurafenib (Zelboraf) yielded durable responses in patients with previously untreated BRAF V600–mutated metastatic melanoma in an ongoing phase Ib study.

Jason Luke on Significance of Biomarker Development for Immunotherapy in Melanoma

January 7th 2016

Jason J. Luke, MD, discusses potential new methods for determining prognostic markers in melanoma and the challenges of balancing toxicity with efficacy in designing combination regimens.

Nivolumab Continues to Improve Outcomes in Advanced Melanoma

January 6th 2016

Victoria Atkinson, MD, discusses the impact of the phase III CheckMate-066 trial and nivolumab’s future as both a monotherapy and in combination with other therapies.

CAR T-Cell Therapy KTE-C19 Shows Promise in Non-Hodgkin Lymphoma

December 22nd 2015

Frederick Locke, MD, discusses the potential for KTE-C19 in non-Hodgkin lymphoma.

Frontline Brentuximab Vedotin Generates 76% Complete Remission Rate in DLBCL

December 22nd 2015

Adding brentuximab vedotin (Adcetris) to frontline R-CHOP produced a greater than 80% response rate—including complete remissions in three-fourths of patients—as a treatment for CD30+ diffuse large B-cell lymphoma.

Venetoclax Improves Outlook for del17p Patients With CLL

December 18th 2015

Stephan Stilgenbauer, MD, discusses the significance of a clinical trial and the impact venetoclax could have on patients with CLL who harbor a 17p deletion.

Hudis on ExteNET, APHINITY, and What's Next for Adjuvant HER2+ Breast Cancer

December 4th 2015

Clifford Hudis, MD, discusses the evolving adjuvant therapy options in HER2-positive breast cancer.

Suresh Ramalingam on Remaining Questions With Checkpoint Inhibitors in NSCLC

December 1st 2015

Suresh Ramalingam, MD, discusses the evolving role of checkpoint inhibitors in lung cancer and what challenges still remain.

Durvalumab/Tremelimumab Combo Shows Promise in NSCLC, Regardless of PD-L1 Status

December 1st 2015

Naiyer A. Rizvi, MD, discusses results of a study looking at the combination of the anti-PD-L1 immune checkpoint inhibitor durvalumab (MEDI4736) with the anti–CTLA-4 monoclonal antibody tremelimumab in patients with advanced non–small cell lung cancer.

James Allison on the Future of Checkpoint Inhibitors in Melanoma

November 30th 2015

James Allison, PhD, discusses the rapidly expanding field of immunotherapy in melanoma.

Oncolytic Immunotherapies Show Benefit in Combinations and as Single Agents in Melanoma

November 25th 2015

Robert Andtbacka, MD, discusses how the role of oncolytic immunotherapies continues to evolve in melanoma and gives a better understanding of what is on the horizon for the novel therapeutics.

Missense HER2 Mutations May Not Respond to Targeted Therapies

November 24th 2015

Not all HER2 genes are capable of causing cancer growth or spread, and thus may also fail to predict response to anticancer drugs that target the gene.

Novel Agents Increasingly Individualize CLL Care

November 24th 2015

William G. Wierda, MD, PhD, gives a better understanding of the changing landscape of chronic lymphocytic leukemia and how treatment options vary among different patient subtypes.

Goy on Going Beyond R-CHOP in Large-Cell Lymphoma

November 19th 2015

Dr. Andre Goy discusses combining novel agents with R-CHOP for the treatment of large-cell lymphoma.

Novel Agents Offer Promise in CLL, But Challenges Remain

November 17th 2015

Dr. Thomas Kipps discusses how challenges in CLL may be met in the future and the impact obinutuzumab, venetoclax, and other novel agents could have on CLL treatment.

NEXT PAGE
PREVIOUS PAGE